TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21915047

Group type: EXPERIMENTAL
Intervention: Intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%)
Number of subjects: 66
Study: 18063230

Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake > 90 mg/day
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake for 6 months
Number of subjects: 608
Study: 17163286

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/day (titrated to 300 mg/day after 3 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 12869833

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based regimen
Number of subjects: 10
Study: 10516747

Group type: EXPERIMENTAL
Intervention: Weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2 on days 1, 8, 15, and 22 for induction; 20 mg/m2 for 4 weeks for consolidation; maintenance with oral 6 mercaptopurine 2 mg/kg/day, subcutaneous cytarabine 1 mg/kg, and oral ZVD 20 mg/m2 on day 1 and day 8 of the third month.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Salvage treatment with 4 weekly oral doses of 40 mg/m2 ZVD after induction failure.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Consolidation treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Induction treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Toxicity outcomes related to treatment.
Number of subjects: 51
Study: 8612115

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2397347

Group type: EXPERIMENTAL
Intervention: Family-based approach (group A) with a significant family member trained as cotherapist at home
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patient-based approach (group B) where only the patient was seen and given home assignments
Number of subjects: 30
Study: 373174

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate (0.5 ml of 2.5% solution)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (0.5 ml of 0.4% solution)
Number of subjects: 130
Study: 31062997

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Number of subjects: 27
Study: 27522121

Group type: EXPERIMENTAL
Intervention: Transition-specific educational program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no program)
Number of subjects: 29
Study: 25814628

Group type: EXPERIMENTAL
Intervention: Nasal inoculation of 10^4 colony-forming units of N. lactamica
Number of subjects: 310

Group type: COMPARATOR
Intervention: Sham inoculation (control group)
Number of subjects: 310
Study: 23710550

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral hygiene instructions
Number of subjects: 63
Study: 22390625

Group type: EXPERIMENTAL
Intervention: 3 months of supervised exercise training (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control intervention (n = 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 months of supervised exercise training
Number of subjects: 40
Study: 19413408

Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration of .08%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No shock condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predictable shock condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpredictable shock condition
Number of subjects: 0
Study: 17395752

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study: 15621558

Group type: EXPERIMENTAL
Intervention: Pregnant women with Type 1 diabetes mellitus
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Normal pregnant women
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diabetic pregnant women
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diabetic pregnant women in 3rd trimester
Number of subjects: 90
Study: 14607696

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) within 24 hours after admission, combined with supportive treatment and traditional Chinese medicine.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-ERCP treatment, combined with supportive treatment and traditional Chinese medicine.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ERCP treatment in mild acute GP patients.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-ERCP treatment in mild acute GP patients.
Number of subjects: 45
Study: 10320861

Group type: EXPERIMENTAL
Intervention: Exercise group (20 half price sessions over 10 weeks at a leisure centre)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High adherers in the exercise group
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 7917359

Group type: EXPERIMENTAL
Intervention: POCAL (prednisone, vincristine, doxorubicin, Ara‐C, thioguanine)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MEA (mitoxantrone, etoposide, Ara‐C)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TAD (daunorubicin, Ara‐C, thioguanine)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LIP (life ingredient profile)
Number of subjects: 22
Study: 3658278

Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g dose)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Cefonicid (1-g dose)
Number of subjects: 199
Study: 31588607

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise intervention for 12 weeks
Number of subjects: 0
Study: 29780106

Group type: EXPERIMENTAL
Intervention: Oral medications on dialysis days
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Oral medications on nondialysis days
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Types of oral medications
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Frequency of oral medications
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Phosphate binders
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Drug burden comparison
Number of subjects: 700
Study: 27142865

Group type: EXPERIMENTAL
Intervention: Low health literacy group
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Insufficient physical activity
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Being overweight
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 739
Study: 25403470

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 400

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 400
Study: 23733796

Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard thermoregulation care
Number of subjects: 104
Study: 20974320

Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg IV
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 75 µg/kg IV
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18467723

Group type: COMPARATOR
Intervention: Bortezomib 1.5 mg/m2 (arm A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 plus irinotecan 125 mg/m2 (arm B)
Number of subjects: 102
Study: 19250108

Group type: EXPERIMENTAL
Intervention: RV apex stimulation
Number of subjects: 117

Group type: COMPARATOR
Intervention: RV mid-septum stimulation
Number of subjects: 117
Study: 15804736

Group type: EXPERIMENTAL
Intervention: ESTring
Number of subjects: 185

Group type: COMPARATOR
Intervention: Vagifem
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 185
Study: 11554655

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily
Number of subjects: 80
Study: 9457396

Group type: EXPERIMENTAL
Intervention: rIL-2 plus IFN-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DLI plus low-dose rIL-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: DLI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose rIL-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of rIL-2 and IFN-alpha
Number of subjects: 0
Study: 7897617

Group type: EXPERIMENTAL
Intervention: Amisulpride 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study: 3310792

Group type: EXPERIMENTAL
Intervention: Air-fluidized beds (Clinitron Therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional therapy (Lapidus Air Float System)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Air-fluidized beds (for sores 7.8 cm2 or greater)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional therapy (for sores 7.8 cm2 or greater)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Air-fluidized beds
Number of subjects: 72
Study: 31991216

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP)
Number of subjects: 282
Study: 31765277

Group type: EXPERIMENTAL
Intervention: Technology-enhanced reading therapy (14 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (delayed therapy)
Number of subjects: 21
Study: 29855167

Group type: EXPERIMENTAL
Intervention: Supraciliary implantation of hema implant (Esnoper V-2000)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intrascleral implantation of hema implant (Esnoper V-2000)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 26579985

Group type: EXPERIMENTAL
Intervention: Second-line therapy with lopinavir/ritonavir (400 mg/100 mg twice daily) plus either 2-3 clinician-selected nucleoside reverse transcriptase inhibitors, raltegravir, or as monotherapy after 12-week induction with raltegravir.
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Control group (first-line therapy failure).
Number of subjects: 1036
Study: 24909636

Group type: EXPERIMENTAL
Intervention: 15 mg/day meloxicam
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 30 mg/day meloxicam
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control cycles (not treated with meloxicam)
Number of subjects: 56
Study: 21875167

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 512
Study: 18835411

Group type: EXPERIMENTAL
Intervention: 15-min brisk semi-self-paced brisk walk
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 25
Study: 17632138

Group type: EXPERIMENTAL
Intervention: Marcaine infiltration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline infiltration (Control)
Number of subjects: 22
Study: 15479936

Group type: EXPERIMENTAL
Intervention: Intensive disease management from a multidisciplinary team for patients with low literacy.
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care after an initial management session for control patients.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intensive disease management from a multidisciplinary team for patients with higher literacy.
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care after an initial management session for control patients with higher literacy.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 217
Study: 11552189

Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia with corticosteroid injection (lidocaine and betamethasone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manipulation under anesthesia without corticosteroid injection
Number of subjects: 24
Study: 11360565

Group type: EXPERIMENTAL
Intervention: Traditional medicine Syndrome Differentiation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 60
Study: 7881451

Group type: EXPERIMENTAL
Intervention: Test drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3148148

Group type: COMPARATOR
Intervention: d-amphetamine (AMP, 5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: phenylpropanolamine (PPA, 75 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: phenylpropanolamine (PPA, 25 mg)
Number of subjects: 17
Study: 28940882

Group type: EXPERIMENTAL
Intervention: R‐Onyx DES
Number of subjects: 75

Group type: COMPARATOR
Intervention: Resolute DES (historical control)
Number of subjects: 75
Study: 27083449

Group type: EXPERIMENTAL
Intervention: Nicotine patch for 6 weeks
Number of subjects: 269
Study: 25257064

Group type: EXPERIMENTAL
Intervention: Vitamins (B6, B12, folic acid)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 23543661

Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 20378736

Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDMA (1.6 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16
Study: 18455087

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study: 16639665

Group type: EXPERIMENTAL
Intervention: Deep lamellar keratoplasty
Number of subjects: 54

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (Control)
Number of subjects: 54
Study: 12582428

Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin for 6 months (group A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin for 12 months (group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Interferon-a (IFN-a) plus ribavirin
Number of subjects: 104
Study: 10458207

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel combined with ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel within a sequential and concomitant chemoradiotherapy concept
Number of subjects: 0
Study: 7536380

Group type: EXPERIMENTAL
Intervention: Digital rectal examination 24 hours before the second PSA determination
Number of subjects: 100

Group type: COMPARATOR
Intervention: No urological manipulation between PSA determinations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 100
Study: 2037789

Group type: EXPERIMENTAL
Intervention: B subunit (BS)‐whole‐cell vaccine
Number of subjects: 2713

Group type: EXPERIMENTAL
Intervention: Whole‐cell vaccine
Number of subjects: 2713

Group type: COMPARATOR
Intervention: Escherichia coli K12 strain placebo
Number of subjects: 2713

Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 2713
Study: 7307546

Group type: EXPERIMENTAL
Intervention: 0.25% pindolol eye drops
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5% pindolol eye drops
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 31843845

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1438

Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 1438
Study: 25834963

Group type: EXPERIMENTAL
Intervention: Just-in-time training (JITT) instructional video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard medical textbooks)
Number of subjects: 0
Study: 26434372

Group type: EXPERIMENTAL
Intervention: Television viewing time
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Electronic games
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Total screen-time
Number of subjects: 264
Study: 23621793

Group type: EXPERIMENTAL
Intervention: BD32S4 needle (32 gauge×4 mm, straight wall)
Number of subjects: 84

Group type: COMPARATOR
Intervention: TR33T5 needle (33-gauge tip and 28-gauge base×5 mm, double-tapered wall)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 84
Study: 22131607

Group type: EXPERIMENTAL
Intervention: BiPAP autoSV Advanced
Number of subjects: 37

Group type: COMPARATOR
Intervention: BiPAP autoSV
Number of subjects: 37

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 37

Group type: COMPARATOR
Intervention: PSG
Number of subjects: 37
Study: 19842576

Group type: COMPARATOR
Intervention: Treatment modalities for psoriasis (exact treatments not specified) for 15 participants over 16 weeks followed by 12 weeks of observation.
Number of subjects: 21
Study: 17578281

Group type: EXPERIMENTAL
Intervention: Modified unilaterally-open expansive laminoplasty (group A)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional unilaterally open-door laminoplasty (group B)
Number of subjects: 138
Study: 15521902

Group type: EXPERIMENTAL
Intervention: Methadone 5‐20 mg 12 hourly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tincture of opium (TOP) 3.33‐10 mg morphine equivalents 12 hourly
Number of subjects: 30
Study: 11725824

Group type: EXPERIMENTAL
Intervention: 2 mg tropisetron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 60
Study: 9874070

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7839305

Group type: EXPERIMENTAL
Intervention: Smectite
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (motility modifying drugs)
Number of subjects: 174
Study: 1699653

Group type: EXPERIMENTAL
Intervention: CHOP + low-dose bleomycin
Number of subjects: 274

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (3 gm/m2/week intravenously with leucovorin rescue)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard-dose methotrexate (30 mg/m2/week orally without rescue)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Follicular large cell lymphoma (with or without diffuse areas)
Number of subjects: 274
Study: 356971

Group type: EXPERIMENTAL
Intervention: Combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease
Number of subjects: 165
Study: 30210590

Group type: EXPERIMENTAL
Intervention: Montelukast for 7 days
Number of subjects: 56
Study: 26810526

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering (target systolic level < 140 mm Hg)
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target systolic level < 180 mm Hg)
Number of subjects: 2630
Study: 24471991

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of lectures and reflective discussions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 42
Study: 22187384

Group type: EXPERIMENTAL
Intervention: Regulation Group (RG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Yoked Group (YG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No Regulation Group (nRG)
Number of subjects: 44
Study: 20887608

Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 26
Study: 18997461

Group type: EXPERIMENTAL
Intervention: TFA-enriched diet (10.4 g TFAs for 4 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Return to habitual diet (1 week after TFA diet)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard diet (0.8 g TFAs)
Number of subjects: 27
Study: 16014054

Group type: EXPERIMENTAL
Intervention: High CRP (≥3.0 mg/L)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 697
Study: 12852533

Group type: EXPERIMENTAL
Intervention: I‐125 (0.87 mCi/source)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pd‐103 (2.54 U/source)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both I‐125 and Pd‐103
Number of subjects: 20
Study: 10551966

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCCs) 2000 factor IX units intravenously
Number of subjects: 16
Study: 8887129

Group type: EXPERIMENTAL
Intervention: Nafarelin (1 microgram/kg up to 100 micrograms)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 31

Group type: COMPARATOR
Intervention: GnRH
Number of subjects: 31
Study: 1341478

Group type: EXPERIMENTAL
Intervention: Sequential treatment with corticoids (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) followed by interferon-alpha (2 MU, 3 times a week for 3 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential treatment with corticoids (same dosage) followed by higher dose interferon-alpha (5 MU, 3 times a week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU, 3 times a week for 4 months) without prior corticoids
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential corticoid/IFN therapy (both doses combined)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon alone therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 6406473

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 3846924

Group type: EXPERIMENTAL
Intervention: Basin bath
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tub bath
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shower bath
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects (not specified type of bath)
Number of subjects: 40
Study: 30983166

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3002